Total Payments
$572,208
2024 Payments
$44,387
Companies
38
Transactions
408
Medicare Patients
359
Medicare Billing
$101,790
Payment Breakdown by Category
Consulting$430,102 (75.2%)
Other$71,575 (12.5%)
Research$37,986 (6.6%)
Travel$22,985 (4.0%)
Food & Beverage$9,559 (1.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $430,102 | 154 | 75.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $57,105 | 56 | 10.0% |
| Unspecified | $37,986 | 24 | 6.6% |
| Travel and Lodging | $22,985 | 43 | 4.0% |
| Honoraria | $10,470 | 4 | 1.8% |
| Food and Beverage | $9,559 | 126 | 1.7% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $4,000 | 1 | 0.7% |
Payments by Type
General
$534,222
384 transactions
Research
$37,986
24 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $91,891 | 84 | $0 (2024) |
| PFIZER INC. | $90,074 | 68 | $0 (2023) |
| Pharmacyclics LLC, An AbbVie Company | $51,779 | 45 | $0 (2023) |
| Celgene Corporation | $43,118 | 13 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $34,919 | 26 | $0 (2024) |
| SECURA BIO, INC. | $29,350 | 3 | $0 (2022) |
| BeiGene USA, Inc. | $24,820 | 23 | $0 (2024) |
| Hikma Pharmaceuticals USA | $19,684 | 7 | $0 (2022) |
| Kite Pharma, Inc. | $13,567 | 10 | $0 (2024) |
| Amgen Inc. | $12,074 | 3 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $44,387 | 42 | ABBVIE INC. ($16,436) |
| 2023 | $63,103 | 54 | Pharmacyclics LLC, An AbbVie Company ($22,654) |
| 2022 | $71,936 | 37 | SECURA BIO, INC. ($28,600) |
| 2021 | $80,476 | 43 | AstraZeneca Pharmaceuticals LP ($13,271) |
| 2020 | $53,516 | 32 | PFIZER INC. ($11,020) |
| 2019 | $90,598 | 71 | PFIZER INC. ($21,840) |
| 2018 | $42,107 | 54 | PFIZER INC. ($21,940) |
| 2017 | $126,085 | 75 | AbbVie, Inc. ($38,087) |
All Payment Transactions
408 individual payment records from CMS Open Payments — Page 1 of 17
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/24/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Consulting Fee | Cash or cash equivalent | $1,350.00 | General |
| Category: ONCOLOGY | ||||||
| 12/23/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $3,280.00 | General |
| 12/20/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Consulting Fee | Cash or cash equivalent | $450.00 | General |
| Category: ONCOLOGY | ||||||
| 12/18/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: Oncology | ||||||
| 12/09/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $113.14 | General |
| Category: Oncology | ||||||
| 12/07/2024 | Genentech USA, Inc. | Gazyva (Biological), Venclexta | Food and Beverage | In-kind items and services | $144.00 | General |
| Category: BioOncology | ||||||
| 12/06/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $102.09 | General |
| Category: Oncology | ||||||
| 12/06/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $60.00 | General |
| 12/06/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $30.00 | General |
| 12/05/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $141.37 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | AstraZeneca UK Limited | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $820.00 | General |
| Category: Oncology | ||||||
| 10/29/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $46.17 | General |
| Category: Oncology | ||||||
| 09/17/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $46.09 | General |
| Category: Oncology | ||||||
| 09/06/2024 | JAZZ PHARMACEUTICALS INC. | RYLAZE (Drug) | Food and Beverage | In-kind items and services | $148.84 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 09/04/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $149.49 | General |
| Category: Oncology | ||||||
| 08/23/2024 | Epizyme, Inc. | — | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| 08/15/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Consulting Fee | Cash or cash equivalent | $1,350.00 | General |
| Category: ONCOLOGY | ||||||
| 07/18/2024 | Celgene Corporation | — | Consulting Fee | Cash or cash equivalent | $1,050.00 | General |
| 07/16/2024 | Genentech USA, Inc. | Venclexta (Biological) | Food and Beverage | In-kind items and services | $82.44 | General |
| Category: BioOncology | ||||||
| 07/15/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $69.28 | General |
| Category: Oncology | ||||||
| 07/09/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| Category: ONCOLOGY | ||||||
| 06/28/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Consulting Fee | Cash or cash equivalent | $1,875.00 | General |
| Category: Oncology | ||||||
| 06/18/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $2,740.00 | General |
| Category: Oncology | ||||||
| 06/17/2024 | Kite Pharma, Inc. | Tecartus (Drug) | Consulting Fee | Cash or cash equivalent | $2,570.00 | General |
| Category: CELLT | ||||||
| 06/15/2024 | Genentech USA, Inc. | Gazyva (Biological), Venclexta | Food and Beverage | In-kind items and services | $73.70 | General |
| Category: BioOncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| INOTUZUMAB OZOGAMICIN CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $14,550 | 7 |
| Study of Ibrutinib and Rituximab in Treatment Naive Follicular Lymphoma | Pharmacyclics LLC, an AbbVie Company | $7,200 | 1 |
| Ph2 ALL | Amgen Inc. | $4,638 | 1 |
| AN OPEN-LABEL, MULTI-CENTER PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC MONOCLONAL ANTIBODY, IN PATIENTS WITH CD20+ B-CELL MALIGNANCIES PREVIOUSLY TREATED WITH CD20-DIRECTED ANTIBODY THERAPY (ELM-1) | Regeneron Pharmaceuticals, Inc. | $3,786 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH ARZERRA RESEARCH | Novartis Pharmaceuticals Corporation | $3,214 | 1 |
| REGN1979-CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $2,373 | 4 |
| REGN1979-Clinical Development Program | Regeneron Pharmaceuticals, Inc. | $2,192 | 8 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 79 | 162 | $126,616 | $22,620 |
| 2022 | 1 | 69 | 132 | $105,302 | $20,147 |
| 2021 | 3 | 112 | 326 | $172,532 | $36,241 |
| 2020 | 3 | 99 | 237 | $122,504 | $22,782 |
Total Patients
359
Total Services
857
Medicare Billing
$101,790
Procedure Codes
10
All Medicare Procedures & Services
10 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 79 | 162 | $126,616 | $22,620 | 17.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 69 | 132 | $105,302 | $20,147 | 19.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 64 | 186 | $97,893 | $21,254 | 21.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 12 | 97 | $44,038 | $8,663 | 19.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 23 | 30 | $20,807 | $4,438 | 21.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 13 | 13 | $9,794 | $1,886 | 19.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 58 | 143 | $69,346 | $12,258 | 17.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 15 | 34 | $21,998 | $4,351 | 19.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 12 | 46 | $20,884 | $4,222 | 20.2% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 14 | 14 | $10,276 | $1,951 | 19.0% |
About Dr. Susan O'brien, M.D
Dr. Susan O'brien, M.D is a Medical Oncology healthcare provider based in Orange, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1669577276.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Susan O'brien, M.D has received a total of $572,208 in payments from pharmaceutical and medical device companies, with $44,387 received in 2024. These payments were reported across 408 transactions from 38 companies. The most common payment nature is "Consulting Fee" ($430,102).
As a Medicare-enrolled provider, O'brien has provided services to 359 Medicare beneficiaries, totaling 857 services with total Medicare billing of $101,790. Data is available for 4 years (2020–2023), covering 10 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Orange, CA
- Active Since 09/14/2006
- Last Updated 06/06/2019
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1669577276
Products in Payments
- IMBRUVICA (Drug) $77,281
- BESPONSA (Biological) $53,350
- Venclexta (Drug) $45,222
- CALQUENCE (Drug) $36,642
- VENCLEXTA (Drug) $30,167
- COPIKTRA (Drug) $28,600
- BRUKINSA (Drug) $26,120
- Oncology TA (Drug) $19,239
- Imbruvica (Drug) $16,069
- Copiktra (Drug) $10,246
- Tecartus (Drug) $9,010
- Lenvima (Drug) $8,206
- Non-Covered $7,892
- Rituxan (Biological) $7,326
- UKONIQ (Drug) $5,063
- Blincyto (Biological) $4,638
- GAZYVA (Biological) $3,545
- ARZERRA (Drug) $3,214
- Strensiq (Drug) $3,200
- Polivy (Biological) $3,000
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Orange
Dr. Farshid Dayyani, M.d., Ph.d, M.D., PH.D
Medical Oncology — Payments: $1.0M
Medical Oncology $1.0M
Angela Fleischman, Md, MD
Medical Oncology — Payments: $231,930
Medical Oncology $231,930
Dr. Sayeh Lavasani, Md, MD
Medical Oncology — Payments: $140,119
Medical Oncology $140,119
Victoria Villaflor, M.d, M.D
Medical Oncology — Payments: $108,593
Medical Oncology $108,593
Dr. Matko Kalac, M.d., Ph.d, M.D., PH.D
Medical Oncology — Payments: $62,363
Medical Oncology $62,363
Ms. Mihaela Cristea, Md, MD
Medical Oncology — Payments: $25,039
Medical Oncology $25,039